1357945-13-1 Usage
Uses
Used in Pharmaceutical Industry:
3-c]pyridine is used as a building block for the synthesis of various pharmaceutical compounds. Its unique structure allows for the development of new drugs with specific properties and therapeutic effects.
Used in Organic Synthesis:
3-c]pyridine is used as an intermediate in the synthesis of various organic compounds. Its reactivity and structural properties make it a valuable molecule for the development of new organic compounds with specific applications.
Used in Material Science:
3-c]pyridine is used in the development of new materials with specific properties. Its unique structure and reactivity make it a promising candidate for the creation of advanced materials for various applications.
Check Digit Verification of cas no
The CAS Registry Mumber 1357945-13-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,5,7,9,4 and 5 respectively; the second part has 2 digits, 1 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1357945-13:
(9*1)+(8*3)+(7*5)+(6*7)+(5*9)+(4*4)+(3*5)+(2*1)+(1*3)=191
191 % 10 = 1
So 1357945-13-1 is a valid CAS Registry Number.
1357945-13-1Relevant articles and documents
MACROCYCLIC COMPOUNDS AND USES THEREOF
-
Paragraph 000633, (2021/08/27)
Described herein are macrocyclic compounds of Formula (I), which can inhibit kinases such as EGFR, including mutant forms such as T790M EGFR mutants. Also described herein are pharmaceutical compositions comprising a compound of Formula (I), or any pharmaceutically acceptable form thereof, processes for their preparation, and use in therapy for the prevention or treatment of cancer. In particular, compounds described herein can be effective for treating EGFR-driven cancers including non-small cell lung cancer (NSCLC).
BICYCLIC FUSED PYRIDINE COMPOUNDS AS INHIBITORS OF TAM KINASES
-
Paragraph 00437, (2019/06/23)
Provided herein are compounds of the Formula (I): and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, wherein Ring A, X1, X2, X3, R1, R2 and R3 are as defined herein